AMARYL 2 MG

Država: Izrael

Jezik: angleščina

Source: Ministry of Health

Kupite ga zdaj

Navodilo za uporabo Navodilo za uporabo (PIL)
01-08-2021
Lastnosti izdelka Lastnosti izdelka (SPC)
11-07-2021
Javno poročilo o oceni Javno poročilo o oceni (PAR)
19-03-2019

Aktivna sestavina:

GLIMEPIRIDE

Dostopno od:

SANOFI ISRAEL LTD

Koda artikla:

A10BB12

Farmacevtska oblika:

TABLETS

Sestava:

GLIMEPIRIDE 2 MG

Pot uporabe:

PER OS

Tip zastaranja:

Required

Izdeluje:

SANOFI S.P.A., ITALY

Terapevtska skupina:

GLIMEPIRIDE

Terapevtsko območje:

GLIMEPIRIDE

Terapevtske indikacije:

Non-insulin-dependent diabetes melitus ( adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

Datum dovoljenje:

2020-05-31

Navodilo za uporabo

                                [לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט	*
[סגירה]
סגור	*
דף הבית [http://www.health.gov.il/]	*
אודות	*
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx]	*
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx]	*
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx]	*
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx]	*
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx]	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3]	*
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx]	*
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx]	*
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx]	*
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx]	*
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx]	*
יחידות המשרד	*
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx]	*
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx]	*
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx]	*
נושאים	*
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx]	*
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/
                                
                                Preberite celoten dokument
                                
                            

Lastnosti izdelka

                                1
Amaryl tabs SPC version 14.1 dated 05.21 based on US SPC approved Dec
2018
1. Name of the medicinal product
AMARYL 1mg, 2mg, 3mg, 4mg
Glimepiride tablets
2. Therapeutic indications
Amaryl is indicated for non-insulin-dependent diabetes melitus
(adult-onset diabetes, type II
diabetes), when diet, regular physical exercise and weight reduction
alone cannot maintain
therapeutically suitable blood glucose levels.
Limitations of Use
AMARYL should not be used for the treatment of type 1 diabetes
mellitus or diabetic
ketoacidosis, as it would not be effective in these settings.
3. DOSAGE AND ADMINISTRATION
3.1 Recommended Dosing
AMARYL should be administered with breakfast or the first main meal of
the day.
The recommended starting dose of AMARYL is 1 mg or 2 mg once daily.
Patients at increased
risk for hypoglycemia (e.g., the elderly or patients with renal
impairment) should be started on 1
mg once daily [see Warnings and Precautions (5.1) and Use in Specific
Populations (8.5, 8.6)].
After reaching a daily dose of 2 mg, further dose increases can be
made in increments of 1 mg or
2 mg based upon the patient’s glycemic response. Uptitration should
not occur more frequently
than every 1 to 2 weeks. A conservative titration scheme is
recommended for patients at
increased risk for hypoglycemia [see Warnings and Precautions (5.1)
and Use in Specific
Populations (8.5, 8.6)].
The maximum recommended dose is 8 mg once daily.
Patients being transferred to AMARYL from longer half-life
sulfonylureas (e.g., chlorpropamide)
may have overlapping drug effect for 1 to 2 weeks and should be
appropriately monitored for
hypoglycemia.
When colesevelam is coadministered with glimepiride, maximum plasma
concentration and total
exposure to glimepiride is reduced. Therefore, Amaryl should be
administered at least 4 hours
prior to colesevelam.
2
4. DOSAGE FORMS AND STRENGTHS
AMARYL is formulated as tablets of:

1 mg (pink, oblong tablets, biplanar with score-line on both sides,
imprinted on both sides).

2 mg (green, tablets, biplana
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Navodilo za uporabo Navodilo za uporabo arabščina 01-08-2021
Navodilo za uporabo Navodilo za uporabo hebrejščina 01-08-2021

Opozorila o iskanju, povezana s tem izdelkom

Ogled zgodovine dokumentov